Table 2.

Baseline demographics and clinical characteristics patients grouped by L-carnitine versus placebo treatment allocation.

Variable	L-carnitine (N = 16)	Placebo (N = 15)	p-value
Age (IQR)	63 (55, 72)	65 (56, 71)	0.66
Race, n (%)
Caucasian	13 (81)	12 (80)	0.93
African American	3 (19)	3 (20)	0.93
Male, n (%)	11 (69)	10 (67)	0.90
Comorbidities, n (%)
Coronary artery disease	4 (25)	3 (20)	0.74
Cerebrovascular accident	1 (6)	3 (20)	0.25
Hypertension	11(69)	11 (73)	0.78
Insulin dependent diabetes	1 (6)	4 (27)	0.12
Non-insulin dependent diabetes	3 (19)	3 (20)	0.93
Chronic Renal Insufficiency	4 (25)	2 (13)	0.41
Malignancy	2 (13)	3 (20)	0.57
SOFA score (IQR)	14 (11.5, 14)	10 (7, 10)	0.01

SOFA - Sequential Organ Failure Assessment Score; IQR – interquartile range